Old Mission Capital’s Addex Therapeutics ADXN Stock Holding History

Old Mission Capital’s Portfolio ADXN Stock Details ADXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,286	Closed	-$62.2K	–	1283
2023 Q1	$62.2K	Buy	3,286 +1,945	+145%	+$49.1K	﹤0.01%	1305
2022 Q4	$16.9K	Buy	+1,341	New	+$19.8K	﹤0.01%	1253
2022 Q3	–	Sell	-1,557	Closed	-$36K	–	957
2022 Q2	$36K	Buy	+1,557	New	+$117K	﹤0.01%	1252

Other funds holding ADXN

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Old Mission Capital's ADXN Position: Q2 2023 in Review

Old Mission Capital sold out of Addex Therapeutics (ADXN) in Q2 2023, closing a stake of 3,286 shares — an estimated $62.2K sold.

Old Mission Capital first reported a position in ADXN in Q2 2022 and held it in 3 quarters. The position peaked at $62.2K in Q1 2023. 3 funds tracked by Wall St. Rank hold ADXN as of Q2 2023.

Old Mission Capital reported no remaining Addex Therapeutics position as of Q2 2023 after selling out during the quarter.
Old Mission Capital sold 3,286 Addex Therapeutics shares in Q2 2023, an estimated $62.2K.
Old Mission Capital first reported a position in Addex Therapeutics in Q2 2022 and held it in 3 quarters.
Old Mission Capital's Addex Therapeutics position peaked at $62.2K in Q1 2023.
3 funds tracked by Wall St. Rank held Addex Therapeutics as of Q2 2023.

Based on Old Mission Capital's 13F filing for Q2 2023, filed 9 Aug 2023.